Sarah Gray, MD MPH
@sarahgraymd.bsky.social
Pulm/CC | lover of lungs w/interest in obstructive lung disease & the care of respiratory health in pregnancy | Endeavor NorthShore, University of Chicago Medicine, Michigan Medicine | She/her
📢 FDA approves Nerandomilast in IPF, first new pulmonary fibrosis drug in over a decade. Slower progression of FVC decline and a (non-significant) trend toward improved mortality (FIBRONEER-IPF, FIBRONEER-ILD)
#pulmsky #ILD #IPF
druganddeviceworld.com/2025/10/02/e...
#pulmsky #ILD #IPF
druganddeviceworld.com/2025/10/02/e...
ERS 2025: Boehringer shares additional data for lung fibrosis therapy
Pooled Phase III data show Boehringer Ingelheim's nerandomilast may reduce death risk in pulmonary fibrosis, IPF and PPF.
druganddeviceworld.com
October 10, 2025 at 2:21 AM
📢 FDA approves Nerandomilast in IPF, first new pulmonary fibrosis drug in over a decade. Slower progression of FVC decline and a (non-significant) trend toward improved mortality (FIBRONEER-IPF, FIBRONEER-ILD)
#pulmsky #ILD #IPF
druganddeviceworld.com/2025/10/02/e...
#pulmsky #ILD #IPF
druganddeviceworld.com/2025/10/02/e...
Reposted by Sarah Gray, MD MPH
A bit of positive news today. FDA has just approved Lenacapavir for PrEP in the US. In clinical trials one injection every 6 months was close to 100% effective in preventing HIV transmission.
PrEP is for everyone who needs it.
www.usatoday.com/story/news/h...
PrEP is for everyone who needs it.
www.usatoday.com/story/news/h...
FDA approves new twice-yearly HIV shot. What to know
The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show prevents new infections.
www.usatoday.com
June 18, 2025 at 7:01 PM
A bit of positive news today. FDA has just approved Lenacapavir for PrEP in the US. In clinical trials one injection every 6 months was close to 100% effective in preventing HIV transmission.
PrEP is for everyone who needs it.
www.usatoday.com/story/news/h...
PrEP is for everyone who needs it.
www.usatoday.com/story/news/h...
Reposted by Sarah Gray, MD MPH
Jan 30, 2025:
“CHEST remains steadfast in our mission to prevent, diagnose, and treat chest diseases using all available means to advance the best patient outcomes. We maintain that striving for health equity is essential to achieving this goal”
www.chestnet.org/newsroom/che...
“CHEST remains steadfast in our mission to prevent, diagnose, and treat chest diseases using all available means to advance the best patient outcomes. We maintain that striving for health equity is essential to achieving this goal”
www.chestnet.org/newsroom/che...
Reaffirming Our Pledge to the Medical Community - American College of Chest Physicians
Considering recent federal directives, CHEST reaffirms its commitment to education and initiatives that advance health equity, reduce barriers to care, and advance the medical profession.
www.chestnet.org
February 2, 2025 at 2:40 PM
Jan 30, 2025:
“CHEST remains steadfast in our mission to prevent, diagnose, and treat chest diseases using all available means to advance the best patient outcomes. We maintain that striving for health equity is essential to achieving this goal”
www.chestnet.org/newsroom/che...
“CHEST remains steadfast in our mission to prevent, diagnose, and treat chest diseases using all available means to advance the best patient outcomes. We maintain that striving for health equity is essential to achieving this goal”
www.chestnet.org/newsroom/che...
Heads up inhaler peeps!
Jan 1 GSK joined AZ and BI for the $35 inhaler list, adding:
Advair, Anoro, Arnuity, Breo, Incruse, Serevent, Trelegy
NOTES
-only for commercial insurance or uninsured. NOT Medicare/Medicaid
-has to be on formulary, no PA/NDC block
Not ideal, but a start
details —>
#pulmsky
Jan 1 GSK joined AZ and BI for the $35 inhaler list, adding:
Advair, Anoro, Arnuity, Breo, Incruse, Serevent, Trelegy
NOTES
-only for commercial insurance or uninsured. NOT Medicare/Medicaid
-has to be on formulary, no PA/NDC block
Not ideal, but a start
details —>
#pulmsky
January 8, 2025 at 2:59 AM
Heads up inhaler peeps!
Jan 1 GSK joined AZ and BI for the $35 inhaler list, adding:
Advair, Anoro, Arnuity, Breo, Incruse, Serevent, Trelegy
NOTES
-only for commercial insurance or uninsured. NOT Medicare/Medicaid
-has to be on formulary, no PA/NDC block
Not ideal, but a start
details —>
#pulmsky
Jan 1 GSK joined AZ and BI for the $35 inhaler list, adding:
Advair, Anoro, Arnuity, Breo, Incruse, Serevent, Trelegy
NOTES
-only for commercial insurance or uninsured. NOT Medicare/Medicaid
-has to be on formulary, no PA/NDC block
Not ideal, but a start
details —>
#pulmsky
Love education about asthma “plus” disorders and other eosinophilic processes. Things like EPGA and ABPA often under recognized in our patients with poor control. Having a basic framework helps increase likelihood of diagnosis and treatment. #pulmsky
Giving one of my favorite talks this week. Fellows usually know that they need to care about eos + pulmonary complaints, but before I put this together I always had trouble organizing my differential. This is how I think about these diseases now.
November 18, 2024 at 5:21 AM
Love education about asthma “plus” disorders and other eosinophilic processes. Things like EPGA and ABPA often under recognized in our patients with poor control. Having a basic framework helps increase likelihood of diagnosis and treatment. #pulmsky